SEC Form 4 · accession 0001127602-17-012348
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas R Staab II
Officer — Senior Vice President and CFO
Period of report
Mar 16, 2017
Accepted (ET)
Mar 20, 2017 · 3:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 16, 2017 | M | 23,955 | $3.78 | A | 141,268 | D | |
| Common Stock | Mar 16, 2017 | M | 12,500 | $1.42 | A | 153,768 | D | |
| Common StockF1 | Mar 16, 2017 | F | 12,308 | $8.80 | D | 141,460 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emp. Stock Option (Right to Buy) | $3.78 | Mar 16, 2017 | M | 23,955 | D | Jul 1, 2012 | Jul 1, 2021 | Common Stock | 23,955 | 59,055 | D |
| Emp. Stock Option (Right to Buy) | $1.42 | Mar 16, 2017 | M | 12,500 | D | Jan 1, 2014 | Jan 1, 2023 | Common Stock | 12,500 | 75,000 | D |
Explanation of responses
- F1Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise.